WSA
PBYI icon

Wall Street Associates’s Puma Biotechnology PBYI Stock Holding History

Wall Street Associates’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,309
Closed -$386K – 334
2015
Q2 		$386K Sell
3,309
-900
-21% -$163K 0.04% 291
2015
Q1 		$994K Sell
4,209
-200
-5% -$42.8K 0.09% 206
2014
Q4 		$834K Hold
4,409
– – 0.08% 209
2014
Q3 		$1.05M Buy
+4,409
New +$905K 0.11% 195

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wall Street Associates's PBYI Position: Q3 2015 in Review

Wall Street Associates sold out of Puma Biotechnology (PBYI) in Q3 2015, closing a stake of 3,309 shares — an estimated $386K sold.

Wall Street Associates first reported a position in PBYI in Q3 2014 and held it in 4 quarters. The position peaked at $1.05M in Q3 2014. 163 funds tracked by Wall St. Rank hold PBYI as of Q3 2015.

  • Wall Street Associates reported no remaining Puma Biotechnology position as of Q3 2015 after selling out during the quarter.
  • Wall Street Associates sold 3,309 Puma Biotechnology shares in Q3 2015, an estimated $386K.
  • Wall Street Associates first reported a position in Puma Biotechnology in Q3 2014 and held it in 4 quarters.
  • Wall Street Associates's Puma Biotechnology position peaked at $1.05M in Q3 2014.
  • 163 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2015.

Based on Wall Street Associates's 13F filing for Q3 2015, filed 12 Nov 2015.